Stephan Moll, MD writes…
Xarelto® is FDA approved for treatment of venous thromboembolism (VTE), prevention of VTE after hip and knee replacement surgery, and for atrial fibrillation. A number of practical management questions are encountered by physicians, pharmacists, and other health care professional taking care of patients on Xarelto®, such as (a) dosing in renal impairment, (b) conversion of a patient on warfarin to Xarelto®, (c) discontinuation of Xarelto® at times of surgery, dental procedures, colonoscopy, and other procedures, and (d) management of bleeding on Xarelto®. These issues may best be addressed in a health care system by the establishment of a structured treatment algorithm/guide/help for the entire hospital or physician practice. Here is the management guideline established at our institution, the University of North Carolina (UNC) Health Care System. The reader is welcome to take the document and modify it to fit his/her institution/practice’s need or use it as a clinical reference. Also, a detailed discussion of Xarelto® use in DVT and PE treatment can be found in the following Clot Connect blog – click here.
Disclosure: I have consulted for Janssen Pharmaceuticals.
Last updated: Jan 11th, 2013